Sars Cov-2 rt-pcr controls

Nattrols are inactivated controls for Diagnostic tests by real time PCR orGenExpet, Cepheid.

Kontroll för SARS-CoV-2 inaktiverad
SARS CoV 2 control for diagnostic Corona virus Labs

Lieven@gentaur.com for more information about nucleic acid controls.

We can deliver next day to all offical government labs in Europe in April 2020. We need your BSL-2 certification before ordering.

NATSARS-ST
NATtrol Coronavirus SARS
Stock
NATMERS-ST
NATtrol MERS-CoV
Stock

OTHER PCR Controls

Molecular Biology – Qualitative Standards-Controls

NATCOV(229E)-ST
NATtrol Coronavirus 229E
NATCOV(NL63)-ST
NATtrol Coronavirus NL63
NATCOV(OC43)-ST
NATtrol Coronavirus OC43

Organisms – Culture Fluids Heat Inactivated

0810024CFHI
Coronavirus
Strain: OC43 – CFHI
  0810228CFHI
Coronavirus
Strain: NL63 – CFHI
0810229CFHI
Coronavirus
Strain: 229E – CFHI

Organisms – Purified Viral Lysate Heat Inactivated

0810024
Coronavirus OC43 Lysate
0810228
Coronavirus NL63 Lysate
0810229
Coronavirus 229E Lysate

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described.In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death.191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients).

Cepheid GenExpert

Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03-1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61-12·23; p<0·0001), and d-dimer greater than 1 μg/L (18·42, 2·64-128·55; p=0·0033) on admission. Median duration of viral shedding was 20·0 days (IQR 17·0-24·0) in survivors, but SARS-CoV-2 was detectable until death in non-survivors. The longest observed duration of viral shedding in survivors was 37 days.

The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/L could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.

Source: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.


Early dynamics of transmission and control of COVID-19: a mathematical modelling study.

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to 95 333 confirmed cases as of March 5, 2020. Understanding the early transmission dynamics of the infection and evaluating the effectiveness of control measures is crucial for assessing the potential for sustained transmission to occur in new areas. Combining a mathematical model of severe SARS-CoV-2 transmission with four datasets from within and outside Wuhan, we estimated how transmission in Wuhan varied between December, 2019, and February, 2020. We used these estimates to assess the potential for sustained human-to-human transmission to occur in locations outside Wuhan if cases were introduced.We combined a stochastic transmission model with data on cases of coronavirus disease 2019 (COVID-19) in Wuhan and international cases that originated in Wuhan to estimate how transmission had varied over time during January, 2020, and February, 2020. Based on these estimates, we then calculated the probability that newly introduced cases might generate outbreaks in other areas.

To estimate the early dynamics of transmission in Wuhan, we fitted a stochastic transmission dynamic model to multiple publicly available datasets on cases in Wuhan and internationally exported cases from Wuhan. The four datasets we fitted to were: daily number of new internationally exported cases (or lack thereof), by date of onset, as of Jan 26, 2020; daily number of new cases in Wuhan with no market exposure, by date of onset, between Dec 1, 2019, and Jan 1, 2020; daily number of new cases in China, by date of onset, between Dec 29, 2019, and Jan 23, 2020; and proportion of infected passengers on evacuation flights between Jan 29, 2020, and Feb 4, 2020. We used an additional two datasets for comparison with model outputs: daily number of new exported cases from Wuhan (or lack thereof) in countries with high connectivity to Wuhan (ie, top 20 most at-risk countries), by date of confirmation, as of Feb 10, 2020; and data on new confirmed cases reported in Wuhan between Jan 16, 2020, and Feb 11, 2020.


FINDINGS


We estimated that the median daily reproduction number (Rt) in Wuhan declined from 2·35 (95% CI 1·15-4·77) 1 week before travel restrictions were introduced on Jan 23, 2020, to 1·05 (0·41-2·39) 1 week after. Based on our estimates of Rt, assuming SARS-like variation, we calculated that in locations with similar transmission potential to Wuhan in early January, once there are at least four independently introduced cases, there is a more than 50% chance the infection will establish within that population.

Our results show that COVID-19 transmission probably declined in Wuhan during late January, 2020, coinciding with the introduction of travel control measures. As more cases arrive in international locations with similar transmission potential to Wuhan before these control measures, it is likely many chains of transmission will fail to establish initially, but might lead to new outbreaks eventually.Wellcome Trust, Health Data Research UK, Bill & Melinda Gates Foundation, and National Institute for Health Research.

KULeuven research group


Coronavirus Disease 2019 (COVID-19): What we know?

In late December 2019, a cluster of unexplained pneumonia cases has been reported in Wuhan, China. A few days later, the causative agent of this mysterious pneumonia was identified as a novel coronavirus. This causative virus has been temporarily named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the relevant infected disease has been named as coronavirus disease 2019 (COVID-19) by the World Health Organization respectively. The COVID-19 epidemic is spreading in China and all over the world now. The purpose of this review is primarily to review the pathogen, clinical features, diagnosis, and treatment of COVID-19, but also to comment briefly on the epidemiology and pathology based on the current evidences. This article is protected by copyright. All rights reserved.


Liver injury during highly pathogenic human coronavirus infections.

The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), the pathogen of 2019 novel coronavirus disease (COVID-19), has posed a serious threat to global public health. The WHO has declared the outbreak of SARS-CoV-2 infection an international public health emergency. Lung lesions have been considered as the major damage caused by SARS-CoV-2 infection. However, liver injury has also been reported to occur during the course of the disease in severe cases. Similarly, previous studies have shown that liver damage was common in the patients infected by the other two highly pathogenic coronavirus – severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), and associated with the severity of diseases. In this review, the characteristics and mechanism of liver injury caused by SARS-CoV, MERS-CoV, as well as SARS-CoV-2 infection were summarized, which may provide help for further studies on the liver injury of COVID-19.


Consensus of Chinese experts on protection of skin and mucous membrane barrier for healthcare workers fighting against coronavirus disease 2019.

Health professions preventing and controlling Coronavirus Disease 2019 are prone to skin and mucous membrane injury, which may cause acute and chronic dermatitis, secondary infection and aggravation of underlying skin diseases. This is a consensus of Chinese experts on protective measures and advice on hand-cleaning- and medical-glove-related hand protection, mask- and goggles-related face protection, UV-related protection, eye protection, nasal and oral mucosa protection, outer ear and hair protection. It is necessary to strictly follow standards of wearing protective equipment and specification of sterilizing and cleaning. Insufficient and excessive protection will have adverse effects on the skin and mucous membrane barrier. At the same time, using moisturizing products is highly recommended to achieve better protection. This article is protected by copyright. All rights reserved.


Impact of international travel and border control measures on the global spread of the novel 2019 coronavirus outbreak.

The novel coronavirus outbreak (COVID-19) in mainland China has rapidly spread across the globe. Within 2 mo since the outbreak was first reported on December 31, 2019, a total of 566 Severe Acute Respiratory Syndrome (SARS CoV-2) cases have been confirmed in 26 other countries. Travel restrictions and border control measures have been enforced in China and other countries to limit the spread of the outbreak.

Vi uppskattar påverkan av dessa kontrollåtgärder och undersöker rollen för flygplatsresor på den globala spridningen av COVID-19-utbrottet. Våra resultat visar att den dagliga risken för att exportera minst ett enda SARS CoV-2-fall från Kina i Kina via internationella resor översteg 95% den 13 januari 2020. Vi fann att 779 fall (95% CI: 632 till 967) skulle ha varit exporteras senast den 15 februari 2020 utan några gränser eller resebegränsningar och att de kinesiska regeringens verkställande av resor hindrade 70,5% (95% CI: 68,8 till 72,0%) av dessa fall. Under de första tre och en halv veckan av genomförandet minskade resebegränsningarna dessutom den dagliga exportgraden med 81,3% (95% CI: 80,5 till 82,1%) i genomsnitt. I detta tidiga stadium av epidemin,


Saminfektioner av SARS-CoV-2 med flera vanliga andningspatogener hos infekterade patienter.

En-cell RNA-seq-dataanalys på receptorn ACE2-uttryck avslöjar den potentiella risken för olika mänskliga organ sårbara för 2019-nCoV-infektion.

Det har varit känt att den nya Coronavirus, 2019-nCoV, som anses likna SARS-CoV och härstammar från Wuhan (Kina), invaderar mänskliga celler via receptorn angiotensinomvandlande enzym II (ACE2). Dessutom kan lungceller som har ACE2-uttryck vara de viktigaste målcellerna under 2019-nCoV-infektion. Vissa patienter uppvisar emellertid också icke-respiratoriska symtom, såsom njursvikt, vilket antyder att 2019-nCoV också kan invadera andra organ.

För att konstruera en riskkarta för olika mänskliga organ analyserade vi datacetterna RNA-sekvensbestämning (scRNA-seq) med en enda cell, härrörande från viktiga fysiologiska humana system, inklusive andnings-, kardiovaskulära, matsmältnings- och urinvägarna. Genom scRNA-seq-dataanalyser identifierade vi de organ som är i riskzonen, såsom lunga, hjärta, matstrupe, njure, urinblåsan och ileum och lokaliserade specifika celltyper (dvs. typ II-alveolära celler (AT2), hjärtceller, proximal tubuli celler i njur-, ileum- och matstrupsepitelcellerna och urotelcellerna i urinblåsan), som är sårbara för 2019-nCoV-infektion. Baserat på resultaten, konstruerade vi en riskkarta som indikerar sårbarheten hos olika organ för 2019-nCoV-infektion. Denna studie kan ge potentiella ledtrådar för ytterligare undersökning av patogenesen och vägen för 2019-nCoV-infektion.


Genetisk evolutionsanalys av 2019 nya coronavirus och coronavirus från andra arter.

Corona Virus Disease 2019 (COVID-19) orsakat av svårt akut respiratoriskt syndrom coronavirus 2 (SARS-CoV-2) är en folkhälsokriminalitet av internationell oro.

Men hittills finns det fortfarande kontroverser om källan till viruset och dess mellanliggande värd. Här hittade vi att det nya coronavirus var nära besläktat med coronavirus som härstammar från fem vilda djur, inklusive Paguma larvata, Paradoxurus hermaphroditus, Civet, Aselliscus stoliczkanus och Rhinolophus sinicus, och var i samma gren av filogenetiska trädet.

Lieven Gevaert, bioingenjör Gentaur Institute